
What is claimed is:

1. Use of:

(i) a therapeutically effective amount of at least one compound of formula (I)



(I), and


(ii) FOLFIRI

in the manufacture of a medicament for treating cancer in a subject whose cancer progressed on at least one prior FOLFIRI regimen,

wherein the FOLFIRI is to be administered to the subject in a therapeutically effective regime.

2. Use of:

(i) a therapeutically effective amount of at least one compound of formula (I)



(I), and

(ii) a therapeutically effective regimen of FOLFIRI


in the manufacture of a medicament for simultaneously:

(a) inhibiting, reducing, and/or diminishing survival and/or self-renewal of cancer stem cells, and

(b) inhibiting, reducing, and/or diminishing survival and/or proliferation of heterogeneous cancer cells

in a subject, wherein the FOLFIRI is to be administered to the subject in a therapeutically effective regimen.

3. Use of a therapeutically effective amount of at least one compound of formula (I)




(I)

in the manufacture of a medicament for re-sensitizing a subject to FOLFIRI and whose cancer progressed on at least one prior FOLFIRI regimen.

4. Use of:

(i) a therapeutically effective amount of at least one compound of formula (I)



(I), and


(ii) FOLFIRI

in the manufacture of a medicament for preventing cancer relapses in a subject,

wherein the FOLFIRI is to be administered to the subject in a therapeutically effective regimen.

5. Use of:

(i) a therapeutically effective amount of at least one compound of formula (I)




(I), and

(ii) FOLFIRI

in the manufacture of a medicament for treating cancer in a subject,

wherein the FOLFIRI is to be administered to the subject in a therapeutically effective regimen.

6. The use according to any one of claims 1-5, wherein the at least one compound of formula (I) is chosen from compounds having formula (I)



(I)

prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.

7. The use according to claim 6, wherein the medicament further comprises a therapeutically effective amount of at least one angiogenesis inhibitor.

8. The use according to claim 7, wherein the at least one angiogenesis inhibitor is chosen from bevacizumab, pharmaceutically acceptable salts of bevacizumab, and solvates of bevacizumab.

9. The use according to claim 8, wherein the at least one angiogenesis inhibitor is present at a dose of 5 mg/kg.

10. The use according to claim 5, wherein the subject had received at least one prior FOLFIRI regimen.

11. The use according to any one of claims 1 -7, wherein the subject's cancer is associated with an aberrant Stat 3 pathway.

12. The use according to claim 11, wherein the cancer associated with an aberrant Stat 3 pathway is chosen from colon adenocarcinoma, rectal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, hepatocellular carcinoma, ovarian cancer, platinum-resistant ovarian cancer, pancreatic adenocarcinoma, breast cancer, triple negative breast cancer, ovarian cancer, cholangiocarcinoma, melanoma, small cell lung cancer, and non-small cell lung cancer.

13. The use according to claim 12, wherein the subject's cancer is advanced, metastatic, unresectable, or recurrent.

14. The use according to claim 12, wherein the subject's cancer is refractory.

15. The use according to any one of claims 1-5, wherein the at least one compound of formula (I) is present at a dose of 480 mg per day.

16. The use according to claim 15, wherein the at least one compound of formula (I) is to be administered in a divided dose.

17. The use according to any one of claims 1-5, wherein the at least one compound of formula (I) is present at a dose of 240 mg twice daily.

18. The use according to any one of claims 1, 2, and 4-5, wherein the therapeutically effective regimen of FOLFIRI comprises an 400 mg/m^2 bi-weekly infusion of leucovorin.

19. The use according to any one of claims 1, 2, and 4-5, wherein the therapeutically effective regimen of FOLFIRI comprises the administration of 5-fluorouracil as an 400 mg/m^2 bolus and an 1200 mg/m^2 bi-weekly infusion.

20. The use according to any one of claims 1, 2, and 4-5, wherein the therapeutically effective regimen of FOLFIRI comprises the administration of an 180 mg/m^2 bi-weekly infusion of irinotecan.

21. The use according to any one of claims 1, 2, and 4-5, wherein said administration of the at least one compound of formula (I) and the FOLFIRI is simultaneous or sequential.